NCT00944645View on ClinicalTrials.gov

MK0524A Bioequivalence Study (0524A-059)

PHASE1CompletedINTERVENTIONAL
Enrollment

188

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions
Dyslipidemia
Interventions
DRUG

niacin (+) laropiprant (Source 1)

Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 1 in one of two treatment periods.

DRUG

Comparator: niacin (+) laropiprant (Source 2)

Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 2 in one of two treatment periods.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00944645 - MK0524A Bioequivalence Study (0524A-059) | Biotech Hunter | Biotech Hunter